Cristina Albrici

Dr. Cristina Albrici

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2023 in Biology
Verified
Journal Article
Open access
PDF file
CTClaudio Tirelli
Claudio Tirelli
MAMara De Amici
Mara De Amici
CACristina Albrici
Cristina Albrici
SMSabrina Mira
Sabrina Mira
GNGiulia Nalesso
Giulia Nalesso
SCStefano Centanni
Stefano Centanni
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative pathogen of coronavirus disease 19 (COVID-19). COVID-19 can manifest with a heterogenous spectrum of disease severity, from mild upper airways infection to severe interstitial pneumonia and devastating acute respiratory distress syndrome (ARDS). SARS-CoV-2 infection may induce an over activation of the immune system and the release of high concentrations of pro-inflammatory cytokines, leading to a “cytokine storm”, a recognized pathogenetic mechanism in the genesis of SARS-CoV-2-induced lung disease. This overproduction of inflammatory cytokines has been recognized as a poor prognostic factor, since it can lead to disease progression, organ failure, ARDS and death. Moreover, the immune system shows dysregulated activity, particularly through activated macrophages and T-helper cells and in the co-occurrent exhaustion of lymphocytes. We carried out a non-systematic literature review aimed at providing an overview of the current knowledge on the pathologic mechanisms played by the immune system and the inflammation in the genesis of SARS-CoV-2-induced lung disease. An overview on potential treatments for this harmful condition and for contrasting the “cytokine storm” has also been presented. Finally, a look at the experimented experimental vaccines against SARS-CoV-2 has been included.

7 November 2024 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
MMMichele Mondoni
Michele Mondoni
RRRocco Francesco Rinaldo*
Rocco Francesco Rinaldo*
CRChristopher J. Ryerson
Christopher J. Ryerson
CACristina Albrici
Cristina Albrici
ABAndrea Baccelli
Andrea Baccelli
SCStefano Centanni
Stefano Centanni
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing and progressive interstitial lung disease of unknown aetiology with a pathogenesis still partly unknown. Several microvascular and macrovascular abnormalities have been demonstrated in the pathogenesis of IPF and related pulmonary hypertension (PH), a complication of the disease.Methods: We carried out a non-systematic, narrative literature review aimed at describing the role of the vasculature in the natural history of IPF.Results: The main molecular pathogenetic mechanisms involving vasculature (i.e.endothelial-to-mesenchymal transition, vascular remodelling, endothelial permeability, occult alveolar haemorrhage, vasoconstriction and hypoxia) and the genetic basis of vascular remodelling are described. The prevalence and clinical relevance of associated PH are highlighted with focus on the vasculature as a prognostic marker. The vascular effects of current antifibrotic therapies, the role of pulmonary vasodilators in the treatment of disease, and new pharmacological options with vascular-targeted activity are described.Conclusions: The vasculature plays a key role in the natural history of IPF from the early phases of disease until development of PH in a subgroup of patients, a complication related to a worse prognosis. Pulmonary vascular volume has emerged as a novel computed tomography finding and a predictor of mortality, independent of PH. New pharmacological options with concomitant vascular-directed activity might be promising in the treatment of IPF.

8 January 2026 in Clinical and Translational Allergy
Verified
Journal Article
Open access
FMFrancesco Menzella
Francesco Menzella
MCMarcello Cottini
Marcello Cottini
EPElena Parazzini
Elena Parazzini
RCRory Chan
Rory Chan
LVLaura Ventura
Laura Ventura
MMMaria Rita Marchi
Maria Rita Marchi

17 July 2025 in Respiratory Medicine
Verified
Journal Article
Open access
CTClaudio Tirelli
Claudio Tirelli
EPElena Maria Parazzini
Elena Maria Parazzini
LSLucia Sacchi
Lucia Sacchi
GCGiulia Carone
Giulia Carone
FPFrancesca Pescol
Francesca Pescol
SCStefano Centanni
Stefano Centanni
Severe asthma affects 3-10 % of asthmatic patients. Biologic therapies can act as disease modifying agents in severe asthma. The prevalence of small airways dysfunction (SAD) increases with asthma severity. Forced Oscillatory Technique (FOT) is a reliable method for studying small airways. The aim of the study was to analyze FOT parameters in a cohort of eosinophilic severe asthma patients naïve of biologic therapy, and to describe the presence of correlation with spirometry data. Variations of FOT parameters after 6 and 12 months from the start of biologic therapy were also prospectively recorded and analyzed. 47 severe eosinophilic asthma patients were consecutively enrolled. FOT, spirometry data, levels of asthma biomarkers, number of exacerbations, Asthma Control Test (ACT) were determined at baseline (T0: patients naïve of biologic treatment) and after 6 and 12 months. at T0, a significant linear correlation was found between R5-19 and FEV1/FVC (Forced expiratory volume in 1 s/Forced Vital Capacity) values (p = 0.0008). At T0, FOT R5-19 values were more elevated in obstructed patients. The cut-off value of R5-19 that best discriminates the presence of obstruction (FEV1/FVC <0.70) was determined at 0.81 cmH2O/(L/s) (sensitivity 0.58, specificity 0.76, ROC-AUC 0.67). A significant relationship was found between FEV1/FVC and FOT R5-19 also after 6 (p = 0.007) and 12 months (p = 0.027) of biologic therapy. No significant correlations were found between any other FOT parameter and blood eosinophils count, FeNO, number of exacerbations or ACT. FOT R5-19 values correlate with FEV1/FVC and are significantly higher in obstruction. This correlation could be explained by the higher resistances of small airways in obstructed patients.

2 June 2026 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
FMFrancesco Menzella
Francesco Menzella
RCRory Chan
Rory Chan
MCMarcello Cottini
Marcello Cottini
MMMichele Mondoni
Michele Mondoni
EPElena Parazzini
Elena Parazzini
MMMaria Rita Marchi
Maria Rita Marchi
1. Severe asthma (SA) is a heterogeneous and debilitating condition, often associated with a high burden of exacerbations, dependence on oral corticosteroids (OCS), and poor quality of life [1–3]. ...

26 April 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
CSCarmine Salerni
Carmine Salerni
STSilvia Terraneo
Silvia Terraneo
MBMichele Bonanomi
Michele Bonanomi
SMSara Mirijaj
Sara Mirijaj
CACristina Albrici
Cristina Albrici
MMMichele Mondoni
Michele Mondoni
Background: Endosonography (i.e., endoscopic ultrasound with bronchoscope fine-needle aspiration, EUS-B-FNA and endobronchial ultrasound-guided transbronchial needle aspiration, EBUS-TBNA) is a widely used technique in the diagnosis and staging of non-small cell lung cancer. Limited data are available in diagnosing small cell lung cancer (SCLC), and no studies have specifically investigated the diagnostic accuracy of EUS-B-FNA in these patients. The study aims at evaluating the sensitivity and safety of endosonography in the diagnosis of SCLC. Methods: A prospective, single-center, observational study was conducted in Italy. All patients diagnosed with SCLC who underwent EUS-B-FNA and/or EBUS-TBNA were enrolled. The sensitivity of EUS-B-FNA and EBUS-TBNA were assessed using pathological confirmation as the gold standard. Results: A total of 72 patients (38 (53%) males) with confirmed SCLC were included in the study. EUS-B-FNA was performed in 31 (43%) patients and EBUS-TBNA in 44 (61.1%) patients; both procedures were performed in three (4.2%). The overall sensitivity of endosonography was 97.2%. The sensitivity of EUS-B-FNA and EBUS-TBNA was 96.8% and 90.9%, respectively. No differences were observed in the sensitivity of both techniques when sampling lymph nodes vs. pulmonary parenchymal lesions (p = 0.99). The overall complication rate was 5.6%. No major complications were reported. Conclusions: Endosonography is a highly accurate and safe technique in diagnosing SCLC. EUS-B-FNA alone demonstrates excellent sensitivity, supporting its extensive role as a valuable diagnostic tool. The combined use of both techniques may further optimize diagnostic yield in the diagnosis of SCLC.